Gyre Therapeutics (GYRE) Short-term Investments (2010 - 2026)

Gyre Therapeutics (GYRE) has 15 years of Short-term Investments data on file, last reported at $12.3 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $12.3 million, down 16.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.3 million (down 16.84% YoY), and the FY2025 annual result was $15.4 million, up 3.36% from the prior year.
• Short-term Investments fell to $12.3 million in Q1 2026 per GYRE's latest filing, from $15.4 million in the prior quarter.
• Over five years, Short-term Investments peaked at $19.6 million in Q3 2025 and troughed at $7.6 million in Q1 2024.
• A 3-year average of $13.4 million and a median of $14.8 million in 2025 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2025 and 2026: Short-term Investments soared 113.55% in 2025, then retreated 16.84% in 2026.
• A 3-year view of Short-term Investments shows it stood at $14.9 million in 2024, then grew by 3.36% to $15.4 million in 2025, then retreated by 20.08% to $12.3 million in 2026.
• Business Quant data shows GYRE's Short-term Investments at $12.3 million in Q1 2026, $15.4 million in Q4 2025, and $19.6 million in Q3 2025.